The hemodynamic and electrocardiographic changes induced by left ventriculography and coronary arteriography with ioxaglate (a new low osmolality angiographic contrast agent) were characterized and compared with the changes induced by a commercial formulation of the commonly used angiographic contrast agent, diatrizoate . Left ventriculography and coronary arteriography were performed in 25 patients utilizing ioxaglate and in another 25 patients utilizing diatrizoate. Both agents increased left ventricular end-diastolic pressure and decreased arteriovenous oxygendifference after left ventriculography, but the magnitude of the increase caused by ioxaglate was significantly less than that caused
The hemodynamic and electrocardiographic changes induced by left ventriculography and coronary arteriography with ioxaglate (a new low osmolality angiographic contrast agent) were characterized and compared with the changes induced by a commercial formulation of the commonly used angiographic contrast agent, diatrizoate (Renografin-76). Left ventriculography and coronary arteriography were performed in 25 patients utilizing ioxaglate and in another 25 patients utilizing diatrizoate. Both agents increased left ventricular end-diastolic pressure and decreased arteriovenous oxygendifference after left ventriculography, but the magnitude of the increase caused by ioxaglate was significantly less than that caused
The commonly used radiographic contrast agent for cardiac and coronary angiography is a 76% solution of the meglumine and sodium salts (66% meglumine and 10% sodium) of diatrizoic acid. This formula has two fundamental shortcomings that impair its efficacy. The first is its hyperosmolality. Seventy-six percent meglumine and sodium diatrizoate (which contains 37% iodine) has an osmolality of 1,600 mosmollkg, which is roughly five times the osmolality of plasma. The second shortcoming is a transient myocardial depressant action that does not appear to be related to the osmolality of the solution (1) (2) (3) (4) (5) (6) (7) (8) . Together these two shortcomings cause an increase in left ventricular filling pressures during the period immediately after injection of contrast agent.
Both agents were well tolerated when used for coronary arteriography with no adverse events occurring in either group. Ioxaglate is a well tolerated cardiac angiographic contrast agent that produces less hemodynamic disturbance than diatrizoate. Accordingly, it may be particularly well suited to use in patients with impaired left ventricular function.
In most patients, this increase is not clinically significant and does not produce symptoms or compromise the extent or quality of the diagnostic study. In other patients, however, particularly those with impaired left ventricular function or severe valvular disease, the degree of contrast agentinduced elevation of left ventricular filling pressures is unacceptable and may cause pulmonary edema. In such patients, the hemodynamic consequences of the contrast agent administration may require abbreviation of, or even preclude, the angiographic portion of the study. Paradoxically, those patients who are least able to tolerate the insult of contrast agent injection frequently have cardiac disease that is so severe and complex that multiple contrast injections are necessary to define the situation completely. A contrast agent that causes less hemodynamic disturbance would be particularly useful for conducting studies in these patients.
During the past decade, there has been an active search for new radiographic contrast agent molecules. A consistent effort has been made to increase the quantity of iodine per osmotically active particle. Ioxaglate is a low osmolality radiographic contrast agent that was synthesized in 1973 (9) . It has been in active clinical use in Europe and South America since 1978. In contrast to diatrizoate, which has 0735-1097/83/$3.00 three iodine atoms per two osmotically active particles, ioxaglate has six iodine atoms per two osmotically active particles. The clinically used formulation of ioxaglate is a 59% solution that contains 32% iodine and has an osmolality of 600 mosmol/kg. A solution containing 37% iodine, which would be equivalent in iodine concentration to 76% diatrizoate, is too viscous for clinical use.
Although its myocardial depressant properties appear to be similar to diatrizoate (10), the lower osmolality of the ioxaglate formulation should cause it to produce less hemodynamic disturbance than other preparations with higher osmolality. In order to test this hypothesis, we have examined the hemodynamic response to left ventriculography with both 59% ioxaglate and a commonly used formulation of 76% diatrizoate.
Methods
Studypatients. Studies were performed on 50 adult patients undergoing routine diagnostic cardiac catheterization with left ventriculography and coronary arteriography. All patients were studied for the evaluation of known or suspected coronary disease. Informed consent was obtained from each patient.
Cardiac catheterization procedure. Standard 7 French
fluid-filled catheters were placed in the left and right ventricles and baseline left and right ventricular pressures were recorded. Arteriovenous oxygen difference measured by oximetry (Instrumentation Laboratory model 282 Co-oximeter) was used as an estimate of cardiac output.
After baseline pressure and cardiac output measurements, left ventriculography was performed using either ioxaglate or diatrizoate as a contrast agent. The ioxaglate formulation was 59% meglumine and sodium ioxaglate and the diatrizoate formulation was a commercially available 76% diatrizoate formula (Renografin-76). The selection of contrast agent was made according to a double blind randomization scheme. Proper catheter position was confirmed with a test injection of 8 to 14 cc of contrast agent followed immediately by a 45 cc injection that was filmed.
Left and right ventricular pressures were measured at I, 2, 3, 4 and 5 minutes after the injection and arteriovenous oxygen difference was measured at I, 3 and 5 minutes after the injection. After completion of these measurements, selective coronary arteriography was performed with the same contrast agent used for left ventriculography.
Statistical analysis. The data were analyzed using double-tailed Student's t tests for grouped data or paired data where appropriate and the Wilcoxon two sample test. There were no differences between the two groups of patients in age, sex, body height and weight, final diagnosis and volume of contrast agent administered. Results are expressed as mean values ± I standard error of the mean.
Results
Hemodynamic effects. The average hemodynamic values for the baseline determinations and the I, 2, 3, 4 and 5 minute postinjection determinations are tabulated in Table  I . Both agents produced a transient rise in left and right ventricular end-diastolic pressures that peaked 3 minutes after the injection and began to decline by the 5th minute. Arteriovenous oxygen difference was also transiently decreased by both agents. Ioxaglate produced a significantly smaller increase in left ventricular end-diastolic pressure than did diatrizoate. The mean value for the rise of left ventricular end-diastolic pressure in the ioxaglate group is skewed upward by the inclusion of a single patient who became agitated and developed a 30 mm Hg increase in left ventricular systolic pressure after the injection. In addition, the left ventricular end-diastolic pressure increased from 36 to 50 mm Hg. This patient's data are principally responsible for the large standard error of the mean in the ioxaglate group.
Seventeen of the 25 patients in the ioxaglate group developed a maximal increase of left ventricular end-diastolic pressure of 4 mm Hg or less after the injection of the contrast agent. Of the 25 patients who received diatrizoate, only 8 developed a left ventricular end-diastolic pressure increase of 4 mm Hg or less and 14 developed an increase of 10 mm Hg or more, compared with only 7 of 25 patients in the ioxaglate group. The difference between the two groups in the magnitude of the left ventricular end-diastolic pressure increase is significant (probability [p] < 0.02).
Both agents increased right ventricular end-diastolic pressure. The magnitudes of the changes were smaller and the differences between the two groups, although similar to those observed for left ventricular end-diastolic pressure, were not as great (p < 0.1).
Both agents produced a decrease in arteriovenous oxygen difference but the maximal decrease produced by ioxaglate ( -0.33 ± 0.19 ml/IOO m!) was significantly less than produced by diatrizoate (-0.85 ± 0.13 mlllOO ml) (p < 0.05).
The two groups did not differ in their baseline hemoglobin concentrations (ioxaglate 15.21 ± 0.42 g/IOO ml, diatrizoate 15.20 ± 0.42 gllOO mI). Both agents produced significant transient hemodilution as evidenced by a decrease in hemoglobin values. However, the maximal decrease in hemoglobin in the ioxaglate group was significantly less than that in the diatrizoate group ( -0.60 ± 0.09 vs. -0.82 ± 0.11 gllOO ml) (p < 0.05). Figures I to  4 , which plot the mean changes of the two groups in left ventricular end-diastolic pressure, right ventricular end-diastolic pressure, arteriovenous oxygen difference and hemoglobin as a function of the time after injection. ~'-----.----,..------.---r--- (mmHg) patients in whom rigid control of all factors affecting measurements of hemodynamic variables could not be accomplished, it is not possible to distinguish between the obvious difference in the osmolalities of the two agents and a possible difference between the two in direct myocardial action
The time course and magnitude of the changes in hemodynamics and hemodilution are illustrated in

Discussion
Ioxaglate versus diatrizoate contrast solutions. These data demonstrate that left ventricular injection of a 59% solution of sodium meglumine ioxaglate clearly produces less hemodynamic disturbance and less hemodilution than does injection of an identical volume of 66% meglumine, 10% sodium diatrizoate. Because the data were obtained in demonstrate that the time course of the changes in these variables produced by the two agents is similar, but that the magnitude of changes produced by ioxaglate is less than that of changes produced by diatrizoate.
Adverse effects. The incidence of adverse effects of the two contrast agents was comparable. Three patients receiving ioxaglate experienced nausea and vomiting immediately after the injection and three patients receiving diatrizoate had similar episodes (p = not significant [NS]). One patient receiving diatrizoate had an anaphylactic reaction that was presumably caused by the contrast agent; this reaction was successfully treated with fluids and epinephrine and no residua occurred. Because the osmolality of the ioxaglate preparation is so much lower than the osmolality of the diatrizoate preparation and because the diatrizoate preparation produced a substantially greater decrease in arteriovenous oxygen difference, it is likely that the osmolality difference constitutes the major reason for the difference we observed. Clinical implications. These data indicate that ioxaglate is a safe and effective contrast agent when used for left ventriculography and coronary arteriography. The data further demonstrate that the ioxaglate formula used produces less hemodynamic disturbance than does a comparable volume of a diatrizoate formulation. This property confers an
